Targeting <i>SLC7A11</i> /xCT improves radiofrequency ablation efficacy of HCC by dendritic cells mediated anti‐tumor immune response
Yuzhao Jin, Songhua Cai, Yang Zhou, Dandan Guo, Yuzhen Zeng, Wangting Xu, Yiting Sun, Yueli Shi, Zhiyong Xu, Zaoqu Liu, Peng Luo, Zhao Huang, Bufu Tang
Abstract
After RFA treatment in patients with liver cancer, the expression of SLC7A11/xCT and the proportion of DCs in the TME were significantly increased. SLC7A11/xCT is a poor prognostic marker for liver cancer and is mainly expressed in DCs in the TME. Targeting xCT in DCs combined with RFA significantly enhances anti-tumor immunity, suppressing tumor growth and offering a promising strategy for improved therapeutic outcomes in liver cancer.
Topics & Concepts
Immune systemRadiofrequency ablationDendritic cellCancer researchMedicineAblationImmunologyInternal medicineAdenosine and Purinergic SignalingMonoclonal and Polyclonal Antibodies ResearchCancer Immunotherapy and Biomarkers